MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Lung Cancer Treatments and Mutations
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,464 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,464 works in the cohort · of 4,299,418page 1 of 50

Labels cover 16 of 2,464 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,464 of 2,464 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affunlabeled
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert +13 more
2005· article· en· New England Journal of Medicine· Medicine
distilled prediction:candidate · noneconsensus · none
5,451
citations
afffundno abstractunlabeled
RECIST 1.1—Update and clarification: From the RECIST committee
Lawrence H. Schwartz, Saskia Litière, Elisabeth G.E. de Vries, Robert Ford, Stephen J. Gwyther, Sumithra J. Mandrekar +13 more
2016· article· en· European Journal of Cancer· Medicine
distilled prediction:candidate · noneconsensus · none
1,894
citations
affunlabeled
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy, Timothy Price, Gerald S. Falchook, Jürgen Wolf +20 more
2021· article· en· New England Journal of Medicine· Medicine
distilled prediction:candidate · noneconsensus · none
1,769
citations
affno abstractunlabeled
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Neal I. Lindeman, Philip T. Cagle, Mary Beth Beasley, Dhananjay Chitale, Sanja Đačić, Giuseppe Giaccone +6 more
2013· article· en· Journal of Thoracic Oncology· Medicine
distilled prediction:candidate · noneconsensus · none
1,284
citations
affunlabeled
EGFR Mutations and Lung Cancer
Gilda da Cunha Santos, Frances A. Shepherd, Ming‐Sound Tsao
2011· review· en· Annual Review of Pathology Mechanisms of Disease· Medicine
distilled prediction:candidate · noneconsensus · none
970
citations
affunlabeled
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Neal I. Lindeman, Philip T. Cagle, Mary Beth Beasley, Dhananjay Chitale, Sanja Đačić, Giuseppe Giaccone +6 more
2013· article· en· Archives of Pathology & Laboratory Medicine· Medicine
distilled prediction:candidate · noneconsensus · none
428
citations
affno abstractunlabeled
Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer☆☆☆☆Abstracted from: Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22:785–94.
William K. Evans
2004· letter· en· Cancer Treatment Reviews· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · metaepi_narrow
406
citations
next →

How this was built: Screen · Findings · About